EMA Authorised: Ponlimsi (denosumab) — Teva GmbH

View source ↗

Summary

The EMA authorised Ponlimsi (denosumab) by Teva GmbH on 19 January 2026 for osteoporosis, including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Ponlimsi (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Teva GmbH. Decision date: 19/01/2026